Abstracts tagged "Systemic sclerosis"

Abstract Number: 1508 • ACR Convergence 2021
Decrease of Angiogenic T Cells Associated to the Presence of Interstitial Lung Disease in Patients with Connective Tissue Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez¹, Fernanda Genre¹, Belén Atienza-Mateo², Victor M. Mora-Cuesta³, David Iturbe-Fernández³, Leticia Lera-Gómez¹, Raquel Perez-Fernández¹, Pilar Alonso-Lecue⁴, Javier Rodriguez-Carrio⁵, Diana Prieto-Peña⁶, Virginia Portilla⁶, Ricardo BLANCO⁷, Alfosno Corrales⁶, José M. Cifrián⁸, Raquel López-Mejías¹ and Miguel Ángel gonzalez-Gay⁹, ¹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System; Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Deparment of Functional Biology, Immunology Area, Faculty of Medicine, Universidad de Oviedo, Oviedo, Asturias, Spain., Oviedo, Spain, ⁶Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Hospital University Marqués de Valdecilla, Santander, Spain, ⁸Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Pneumology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain, ⁹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) is one of the most significant complications of connective tissue diseases (CTD) leading to an increase of the morbidity and…
Abstract Number: 1853 • ACR Convergence 2021
Scleroderma Presentation in the Canadian Scleroderma Research Group Indigenous Population
Curtis Sobchak, Karen Beattie and Maggie Larche, McMaster University, Hamilton, ON, Canada
Background/Purpose: Given the well-known burden of rheumatic disease in Canadian Indigenous populations, the Canadian Rheumatology Association (CRA) has highlighted Aboriginal Rheumatology as an area needing…
Abstract Number: L09 • ACR Convergence 2020
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
Dinesh Khanna¹, Christopher Denton², Daniel Furst³, Maureen Mayes⁴, Marco Matucci-Cerinic⁵, Vanessa Smith⁶, Dick de Vries⁷, Liesbeth Deberdt⁸, Pieter‑Jan Stiers⁸, Niyati Prasad⁸ and Sohail Ahmed⁹, ¹University of Michigan, Ann Arbor, MI, ²Royal Free Hospital, University College London, London, United Kingdom, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Università degli Studi di Firenze, Firenze, Italy, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Galapagos BV, Leiden, Netherlands, ⁸Galapagos NV, Mechelen, Belgium, ⁹Ahmed Science Medicine, Basel, Switzerland
Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…
Abstract Number: 0382 • ACR Convergence 2020
Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis
Melody Chung¹, Kathleen Kolstad², Makdine Dontsi³, Poonam Manwani⁴, Hongyu Zhao⁵, Debbie Postlethwaite³, Sumana Kesh⁶, Julia Simard⁷ and Lorinda Chung⁸, ¹Stanford University, Stanford, CA, ²Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ³Division of Research, Kaiser Permanente Northern California, Oakland, CA, ⁴UCLA-Olive View Rheumatology Fellowship, Los Angeles, CA, ⁵Department of Internal Medicine, Kaiser Permanente Santa Clara, Santa Clara, CA, ⁶Kaiser Permanente Santa Clara, Santa Clara, CA, ⁷Stanford Medicine, Stanford, CA, ⁸Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA
Background/Purpose: Vasculopathy and immune dysfunction likely precede the diagnosis of systemic sclerosis (SSc) by years as evidenced by longstanding Raynaud’s phenomenon prior to diagnosis. Poor…
Abstract Number: 0918 • ACR Convergence 2020
Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
Kristin Highland¹, Gerard Criner², Petros Sfikakis³, Hilario Nunes⁴, Wendy Stevens⁵, Corinna Miede⁶, Margarida Alves⁷ and Michael Kreuter⁸, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ³National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ⁵Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia, Fitzroy, Victoria, Australia, ⁶mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, Heidelberg, Germany
Background/Purpose: Gastroesophageal reflux disease (GERD) is a common comorbidity in patients with SSc-ILD and may be associated with progression of SSc-ILD. In the SENSCIS trial…
Abstract Number: 1383 • ACR Convergence 2020
Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Yasir Suleman¹, Kristina Clark², Svetlana Nihtyanova³, Voon Ong⁴ and Christopher Denton², ¹Royal Free Hospital London NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ⁴UCL, London, United Kingdom
Background/Purpose: Recent Phase II (faSScinate) and Phase III (focuSSced) clinical trials of tocilizumab versus placebo in early dcSSc highlighted the potential impact of tocilizumab on…
Abstract Number: 1915 • ACR Convergence 2020
Leptin Plays a Critical Role in Modulating Dermal Adipose Tissue, Inflammation and Skin Fibrosis
Roberta Goncalves Marangoni¹, Stacey Duemmel², Marc Nuzzo², Christopher Ritchlin³ and Benjamin Korman³, ¹University of Rochester Medical Center, Rochester, NY, ²Department of Medicine, University of Rochester Medical Center, Rochester, ³Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: We previously demonstrated that systemic sclerosis (SSc) patients have substantial reduction in dermal white adipose tissue (dWAT) which correlates with skin fibrosis. In animal…
Abstract Number: 0387 • ACR Convergence 2020
Altered Iron Homeostasis and Pulmonary Haemodynamics in Systemic Sclerosis Associated Pulmonary Arterial Hypertension
Alper Sari¹, Christopher Denton², Svetlana Nihtyanova³, Benjamin Schreiber⁴ and Voon Ong³, ¹Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ²University College London, London, United Kingdom, ³Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ⁴UCL, London, United Kingdom
Background/Purpose: Iron deficiency (ID) is more frequent in systemic sclerosis (SSc) patients with pulmonary hypertension (PH) than those without and associated with worse prognosis. There…
Abstract Number: 0924 • ACR Convergence 2020
Towards Systemic Sclerosis Rehabilitation via Videogames
Marica Doveri¹, Marco Trombini², Federica Ferraro³, Rossana Galli¹, Anna Laura Bargeri⁴, Simone Rando¹, SIlvana Dellepiane² and Gerolamo Bianchi¹, ¹Hospital La colletta Arenzano(Genoa), Arenzano, Liguria, Italy, ²Department of Electrical, Electronics and Telecommunication Engineering and Naval Architecture (DITEN), University of Genoa, GENOVA, Liguria, Italy, ³Department of Electrical, Electronics and Telecommunication Engineering and Naval Architecture (DITEN), University of Genoa, Ponsacco, Liguria, Italy, ⁴Hospital La colletta Arenzano(Genoa), Arenzano, Italy
Background/Purpose: The excessive production and accumulation of collagen in systemic sclerosis (SSc) leads to the gradual loss of mobility which affects the quality of life…
Abstract Number: 1387 • ACR Convergence 2020
Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction?
Megan Meier¹, Jacob Stever², Josephine Wright¹, Tracy Frech³, Greg Stoddard¹ and Benjamin Tingey¹, ¹University of Utah, Salt Lake City, ²University of Utah, SANDY, ³University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: Scleroderma renal crisis (SRC) is a well-characterized condition in patients with systemic sclerosis, but systemic sclerosis patients frequently develop chronic kidney disease (CKD) without…
Abstract Number: 2033 • ACR Convergence 2020
Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
Brian Skaug¹, Marka Lyons¹, William Swindell², Gloria Salazar¹, Julio Charles¹, Connor Vershel¹, Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²The Jewish Hospital, Department of Internal Medicine, Cincinnati, OH, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Numerous studies have revealed dysregulated gene expression in the skin of systemic sclerosis (SSc) patients, with varying degrees of inflammatory/immune and fibroblast upregulation. However,…
Abstract Number: 0388 • ACR Convergence 2020
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
Masataka Kuwana¹, Shervin Assassi², Jérôme Avouac³, Rachel Hoyles⁴, Janet Pope⁵, Vanessa Smith⁶, Corinna Miede⁷, Emmanuelle Clerisme-Beaty⁸, Margarida Alves⁹ and Oliver Distler¹⁰, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ²University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ³Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris Descartes University, France, Paris, France, ⁴Department of Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ⁷mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim, Germany, Ingelheim, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁰Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The progression of SSc-ILD is variable and unpredictable. However, observational studies have identified patient characteristics that may be prognostic of a greater rate of…
Abstract Number: 0925 • ACR Convergence 2020
Early Hydroxychloroquine Use May Reduce Risk for SSc-Associated Pulmonary Hypertension
Alexandra Boucher¹, Yongseok Park², Shannon Zalewski³, Maureen Laffoon², Thomas Medsger⁴, Robert Lafyatis² and Robyn Domsic⁵, ¹University of Pittsburgh, Camp Hill, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Washington University Barnes Jewish Hospital, Saint Louis, MO, ⁴University of Pittsburgh School of Medicine, Verona, PA, ⁵University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) patients are at high risk for pulmonary hypertension (PH), a leading cause of death in this population. Chloroquine is a pulmonary…
Abstract Number: 1388 • ACR Convergence 2020
A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Elizabeth Volkmann³, Laura Hummers⁴, Fredrick Wigley⁵ and Zsuzsanna McMahan⁶, ¹JHUSOM, Baltimore, ²JHUSPH, Baltimore, ³University of California, Los Angeles, Los Angeles, CA, ⁴Johns Hopkins Univerisity, Ellicott City, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University, Baltimore
Background/Purpose: Colonic dysmotility affects up to 50% of patients with systemic sclerosis (SSc). While some patients have mild colonic disease, others experience severe complications, such…
Abstract Number: 2035 • ACR Convergence 2020
Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design
Robyn Domsic¹, Shiyao Gao², Maureen Laffoon², Steven Wisniewski³, Robert Lafyatis⁴, Virginia Steen⁵ and Thomas Medsger⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Arlington, MA, ⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁶University of Pittsburgh School of Medicine, Verona, PA
Background/Purpose: Clinical trials in early diffuse systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome have been largely negative. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].